Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

Inclusion Criteria:

• Has participated in a qualifying tulisokibart Phase 2 or Phase 3 parent study for CDor UC

• The investigator determines that the participant derives clinical benefit fromcontinued study intervention based upon clinical evaluations performed during theirparent study

• A participant assigned female sex at birth is not breastfeeding during the studyintervention period and for at least 14 weeks after the last dose of studyintervention

• A participant of childbearing potential (POCBP) is not pregnant and has a negativehighly sensitive pregnancy test (urine or serum) as required by local regulationswithin 24 hours (for a urine test) or 72 hours (for a serum test) before the firstdose of study intervention

• A POCBP uses an acceptable contraceptive method, or adheres to penile-vaginalintercourse abstinence as their preferred and usual lifestyle (abstinent on along-term and persistent basis)

Exclusion Criteria:

• Has prematurely discontinued study intervention in their parent study

• Has received any protocol-specified prohibited medications during their parent study

• Has known allergies, hypersensitivity, or intolerance to tulisokibart or itsexcipients